Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Controversy exists regarding the potential regenerative influences of incretin therapy on pancreatic β-cells versus possible adverse pancreatic proliferative effects. Examination of pancreata from age-matched organ donors with type 2 diabetes mellitus (DM) treated by incretin therapy (n = 8) or other therapy (n = 12) and nondiabetic control subjects (n = 14) reveals an ∼40% increased pancreatic mass in DM treated with incretin therapy, with both increased exocrine cell proliferation (P < 0.0001) and dysplasia (increased pancreatic intraepithelial neoplasia, P < 0.01). Pancreata in DM treated with incretin therapy were notable for α-cell hyperplasia and glucagon-expressing microadenomas (3 of 8) and a neuroendocrine tumor. β-Cell mass was reduced by ∼60% in those with DM, yet a sixfold increase was observed in incretin-treated subjects, although DM persisted. Endocrine cells costaining for insulin and glucagon were increased in DM compared with non-DM control subjects (P < 0.05) and markedly further increased by incretin therapy (P < 0.05). In conclusion, incretin therapy in humans resulted in a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia and the latter by α-cell hyperplasia with the potential for evolution into neuroendocrine tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pancreatic, intestinal, and breast neoplasms were more frequently developed in rodents administered with incretin-based medications”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1788]
Experimental — accuracy not yet measuredIn the citing paper
“these results were not confirmed in human studies [56–58].”
From Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? (2021) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Self-citationXu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Conversion of adult pancreatic α-cells to β-cells after extreme β-cell loss
Thorel, F., Népote, V., Avril, I., Kohno, K., Desgraz, R., Chera, S., & Herrera, P. L. (2010) · Nature · doi:10.1038/nature08894 · Cited by 1,136
Hruban, R. H., Takaori, K., Klimstra, D. S., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Biankin, S. A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000126675.59108.80 · Cited by 1,091
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Self-citationZulewski, H., Abraham, E. J., Gerlach, M. J., Daniel, P. B., Moritz, W., Müller, B., Vallejo, M., Thomas, M. K., & Habener, J. F. (2001) · Diabetes · doi:10.2337/diabetes.50.3.521 · Cited by 785
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea
Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020735 · Cited by 649
Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U. (1985) · Pathology and Immunopathology Research · doi:10.1159/000156969 · Cited by 577
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Cited by
Items 201–300 of 460
Kuo, C.-C., Chuang, M., Li, C., Tsai, Y., Huang, P., Kuo, H., & Lai, C.-C. (2025) · Diabetologia · doi:10.1007/s00125-025-06453-z · Cited by 22
Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial
Gamborg, M., Grand, M. K., Grell, K., Rosthøj, S., Pedersen‐Bjergaard, U., Torp-Pedersen, C. T., & Mørch, L. S. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101346 · Cited by 32
Something old, something new and something very old: drugs for treating type 2 diabetes
Kaiser, D., & Oetjen, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12624 · Cited by 24
de Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 21
Ueberberg, S., Jütte, H., Uhl, W. H., Schmidt, W. E., Nauck, M. A., Montanya, E., Tannapfel, A., & Meier, J. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12766 · Cited by 19
Diabetes medication pharmacology
Stubbs, D. J., Levy, N., & Dhatariya, K. (2016) · BJA Education · doi:10.1093/bjaed/mkw075 · Cited by 23
GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach
Crisci, I., Aragona, M., Politi, K. S., Daniele, G., & Prato, S. D. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0800-6 · Cited by 19
Tseng, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1091944 · Cited by 19
Chou, O. H. I., Zhou, J., Mui, J. V., Satti, D. I., Chung, C. T., Lee, T. T. L., Lee, S., Dee, E. C., Ng, K., Cheung, B. M. Y., et al. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100115 · Cited by 19
Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice
Cox, A. R., Lam, C. J., Rankin, M. M., Rios, J. S., Chavez, J., Bonnyman, C. W., King, K. B., Wells, R. A., Anthony, D., Tu, J. X., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00027 · Cited by 19
Legøy, T. A., Ghila, L., Vethe, H., Abadpour, S., Mathisen, A. F., Paulo, J. A., Scholz, H., Ræder, H., & Chera, S. (2019) · Acta Physiologica · doi:10.1111/apha.13433 · Cited by 18
On behalf of the KIND-LM study investigators, Tanaka, K., Saisho, Y., Manesso, E., Tanaka, M., Meguro, S., Irie, J., Sugiura, H., Kawai, T., Jinzaki, M., et al. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0331-5 · Cited by 20
Vicentini, M., Ballotari, P., Venturelli, F., Ottone, M., Manicardi, V., Gallo, M., Greci, M., Pinotti, M., Pezzarossi, A., & Rossi, P. G. (2022) · Cancers · doi:10.3390/cancers14112719 · Cited by 17
Tuersun, A., Hou, G., & Cheng, G. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.06.015 · Cited by 19
Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review
Goldenberg, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.852078 · Cited by 18
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
Increasing beta cell mass to treat diabetes mellitus
Sabir, S., Saleem, A., Akhtar, M. F., Saleem, M., & Raza, M. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/74452 · Cited by 18
Xie, J., Xie, P., Guo, M. L., Li, F., Xiao, M., Qi, Y.-S., Pei, W., Luo, H.-T., Gu, Y., & Piao, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1215150 · Cited by 18
GLP-1 receptor agonists in the treatment of Type 2 diabetes
Åhrén, B. (2013) · Diabetes Management · doi:10.2217/dmt.13.41 · Cited by 18
Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
Ross, S. A., & Ballantine, J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.837817 · Cited by 16
Yuand, M. B. L. V. E. (2013) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000084 · Cited by 18
Liu, Y., Tian, Q., Yang, J., Wang, H., & Hong, T. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3061 · Cited by 18
Beta-cell function and human islet transplantation: can we improve?
Chen, J. H., & Gunton, J. E. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0590 · Cited by 16
Revisiting Regulators of Human β-cell Mass to Achieve β-cell–centric Approach Toward Type 2 Diabetes
Sasaki, H., Saisho, Y., Inaishi, J., & Itoh, H. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab128 · Cited by 18
Shilleh, A. H., & Russ, H. A. (2023) · Cells · doi:10.3390/cells12050698 · Cited by 20
Sitagliptin‐induced pancreatitis – a longer road than expected
Nelson, M., Bhandari, N., & Wener, J. (2014) · Clinical Case Reports · doi:10.1002/ccr3.83 · Cited by 15
Engel, S. S., Golm, G. T., & Lauring, B. P. (2013) · Diabetes · doi:10.2337/db13-0525 · Cited by 15
Exploring the potential impact of GLP-1 receptor agonists in cancer therapy
Aslam, B., Zafar, M. D. B., Changez, M. I. K., ABDULLAH, M., Safwan, M., QAMAR, B., SHINWARI, A., & Sanjana, R. A. I. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.04101-5 · Cited by 21
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Pratley, R. E., Saeed, Z. I., & Casu, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001057 · Cited by 16
Fawzy, M. S., Alenezy, A. K., Jishu, J. A., Khan, I., Dessouky, A., Abdelmaksoud, A., Limbach, K. E., & Toraih, E. A. (2025) · Cancers · doi:10.3390/cancers17091593 · Cited by 15
What's next after metformin? focus on sulphonylurea: add-on or combination therapy
Lim, P. C., & Chong, C. P. (2015) · Pharmacy Practice · doi:10.18549/pharmpract.2015.03.606 · Cited by 20
Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer
Cases, A. I., Ohtsuka, T., Kimura, H., ZHENG, B., Shindo, K., Oda, Y., Mizumoto, K., Nakamura, M., & Tanaka, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4138 · Cited by 15
Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells
Ebou, M. H., Singh‐Estivalet, A., Launay, J., Callebert, J., Tronche, F., Ferré, P., Gautier, J., Guillemain, G., Bréant, B., Blondeau, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149343 · Cited by 19
European drugs agency clashes with scientists over safety of GLP-1 drugs
Cohen, D. (2013) · BMJ · doi:10.1136/bmj.f4838 · Cited by 14
Use of Non-Insulin Therapies for Type 1 Diabetes
Garg, S. K., Michels, A. W., & Shah, V. N. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0281 · Cited by 15
De Sousa, S. M. C., Haghighi, K. S., Qiu, M. R., Greenfield, J. R., & Chen, D. L. T. (2016) · Pancreas · doi:10.1097/mpa.0000000000000430 · Cited by 13
Zhong, Y., Wu, T., & Khan, N. U. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04211-4 · Cited by 19
Ke, W., Liu, L., Liu, J., Chen, A., Deng, W., Zhang, P., Cao, X., Liao, Z., Xiao, H., Liu, J., et al. (2015) · Journal of Diabetes Research · doi:10.1155/2016/6839735 · Cited by 14
Roy, D., Chadwick, K. D., Tatarkiewicz, K., LaCerte, C., Bergholm, A., Brodie, T., Mangipudy, R. S., Parkes, D. G., Graziano, M. J., & Reilly, T. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12294 · Cited by 13
Hernandez-Rienda, L., Olmo-García, M. I. D., & Merino-Torres, J. F. (2022) · Metabolites · doi:10.3390/metabo12111103 · Cited by 14
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice
Triplitt, C. L., & Solis‐Herrera, C. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607981 · Cited by 16
Human β-cell regeneration: progress, hurdles, and controversy
Jurczyk, A., Bortell, R., & Alonso, L. C. (2014) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000042 · Cited by 15
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Kristin, E. (2016) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci004802201606 · Cited by 18
Antidiabetic therapy in post kidney transplantation diabetes mellitus
Werzowa, J. M., Säemann, M. D., Haidinger, M., Krebs, M., & Hecking, M. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.01.001 · Cited by 14
Liatis, S., Papaoikonomou, S., GANOTOPOULOU, A., Papazafiropoulou, A. K., Dinos, C., Michail, M., Xilomenos, A., Melidonis, A. J., & Pappas, S. I. (2014) · BMC Endocrine Disorders · doi:10.1186/1472-6823-14-23 · Cited by 16
Improving Translational Paradigms in Drug Discovery and Development
Williams, M. J. (2021) · Current Protocols · doi:10.1002/cpz1.273 · Cited by 12
Incretin-based therapy and pancreatic beta cells
Chon, S., Riveline, J., Blondeau, B., & Gautier, J. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.05.003 · Cited by 13
Heine, R. J., Fu, H., Kendall, D. M., & Moller, D. E. (2013) · Diabetes · doi:10.2337/db13-0690 · Cited by 16
Butler, A. E., Campbell‐Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M. A., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db13-0996 · Cited by 12
Self-citationPancreatic Safety of Newer Incretin-Based Therapies: Are the “-tides” Finally Turning?
Devaraj, S., & Maitra, A. (2014) · Diabetes · doi:10.2337/db14-0545 · Cited by 12
Vahle, J. L., Byrd, R. A., Blackbourne, J. L., Martin, J. A., Sorden, S. D., Ryan, T. E., Pienkowski, T. P., Rosol, T. J., Snyder, P. W., & Klöppel, G. (2015) · Toxicologic Pathology · doi:10.1177/0192623315588999 · Cited by 11
Molecular Basis of cAMP Signaling in Pancreatic β Cells
Holz, G. G., Chepurny, O. G., Leech, C. A., Song, W., & Hussain, M. A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_25 · Cited by 12
Use of Glucagon-Like Peptide-1 Agonists to Improve Islet Graft Performance
Wang, Y., Qi, M., McGarrigle, J. J., Rady, B., Davis, M., Vaca, P., & Oberholzer, J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0402-z · Cited by 15
Egan, J. M., & Chia, C. W. (2014) · Diabetes · doi:10.2337/db13-1909 · Cited by 12
Guimarães, M., Rodrigues, P., Pereira, S. S., Nora, M. C., Gonçalves, G., Albrechtsen, N. J. W., Hartmann, B., Holst, J. J., & Monteiro, M. P. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-15-0049 · Cited by 13
β-Cell Identity in Type 2 Diabetes: Lost or Found?
Butler, A. E., & Dhawan, S. (2015) · Diabetes · doi:10.2337/db15-0550 · Cited by 16
Self-citationKubota, S., Haraguchi, T., Kuwata, H., Seino, Y., Murotani, K., Tajima, T., Terashima, G., Kaneko, M., Takahashi, Y., Takao, K., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13921 · Cited by 10
Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
Vigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.007 · Cited by 13
Haluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy
Hakim, M., Fathi, M. A., Abdulraziq, M., & Shehri, M. A. A. (2022) · Surgical Endoscopy · doi:10.1007/s00464-022-09294-8 · Cited by 11
Glucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
Liraglutide-Induced Hemorrhagic Pancreatitis in a Nondiabetic Patient
Dolan, R. D., Bazarbashi, A. N., Lo, A., & Smith, B. N. (2020) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000380 · Cited by 10
Heterotopic pancreas in excluded stomach diagnosed after gastric bypass surgery
Guimarães, M., Rodrigues, P., Gonçalves, G., Nora, M. C., & Monteiro, M. P. (2013) · BMC Surgery · doi:10.1186/1471-2482-13-56 · Cited by 10
Linagliptin-Induced Pancreatitis
Mosquera, J. E., Torres, N. B., Restrepo, J., Ruz-Pau, C., & Suryanarayanan, S. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0307 · Cited by 10
A Diabetic Patient Complicated With Pancreatic Cancer After Using Liraglutide: A Case Report
Wu, S., Wang, J., Li, J., & Chen, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.608966 · Cited by 10
A review of the last decade: pancreatic cancer and type 2 diabetes
Wu, J., Tang, L., Zheng, F., Chen, X., & Li, L. (2023) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2023.2252204 · Cited by 9
Covington, B. A., & Chen, W. (2024) · Biomedicines · doi:10.3390/biomedicines12030473 · Cited by 12
Glucagon-like peptide-1 receptor agonists
Gallwitz, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-08982-9_3 · Cited by 9
Lahiri, S. W. (2017) · Clinical Diabetes · doi:10.2337/cd17-0083 · Cited by 11
Rouse, R. L., Zhang, L. W., Shea, K. I., Zhou, H., Xu, L., Stewart, S. R., Rosenzweig, B. A., & Zhang, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109477 · Cited by 11
McGill, A. (2014) · Archives of Public Health · doi:10.1186/2049-3258-72-31 · Cited by 11
Incretin manipulation in diabetes management
Pappachan, J. M., Raveendran, A. V., & Sriraman, R. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.774 · Cited by 10
Wei, Q., Huang, L., Li, J., Chen, B., Xie, B., Teng, H., Chen, L., & Jiang, Y. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13170 · Cited by 9
Patel, V., Pandya, C. V., Pandya, A., Patel, D., & Patel, Z. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00717 · Cited by 9
Clinical Pharmacology of Dipeptidyl Peptidase 4 Inhibitors: Comparative Review
Sidorov, A. V. (2020) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2020-16-25-24-48 · Cited by 12
Wada, R., & Yagihashi, S. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9326-7 · Cited by 8
Treatment of Autoimmune Diabetes by Inhibiting the Initial Event
Lee, M. (2013) · Immune Network · doi:10.4110/in.2013.13.5.194 · Cited by 8
A systematic review of the safety of incretin-based therapies in type 2 diabetes
Evans, M., Bain, S. C., & Vora, J. P. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.1057502 · Cited by 8
Acute Pancreatitis Likely Due to Semaglutide
Hughes, K., Sumaruth, Y. R. K., Mohammed, E., & Bakshsingh, V. S. (2024) · Cureus · doi:10.7759/cureus.69844 · Cited by 17
Sayıner, Z. A., Demiroğlu, G. İ., Akarsu, E., & Araz, M. (2018) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2018.83788 · Cited by 8
Deficiency of transcription factor Nkx6.1 does not prevent insulin secretion in INS-1E cells
Pavluch, V., Engstová, H., Špačková, J., & Ježek, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-27985-7 · Cited by 9
Diabetes, Antihyperglycemic Medications and Cancer Risk: Smoke or Fire?
Gallagher, E. J., & LeRoith, D. (2013) · Endocrine Practice · doi:10.4158/ep13190.ra · Cited by 8
Cardiovascular benefits of incretins
Barnett, A. H., & O'Hare, P. J. (2013) · BMJ · doi:10.1136/bmj.f4382 · Cited by 8
Hyperplasia from GLP-1 drugs is "not a surprise," say researchers
Cohen, D. (2013) · BMJ · doi:10.1136/bmj.f2025 · Cited by 8
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues
Molin, M. D., Kim, H., Blackford, A. L., Sharma, R. B., & Goggins, M. (2015) · Pancreas · doi:10.1097/mpa.0000000000000521 · Cited by 10
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
Smoke or Fire? Acute Pancreatitis and the Liraglutide Trials
Gale, E. A. (2015) · Diabetes Care · doi:10.2337/dc15-0346 · Cited by 7
Resistance to Obesity in SOD1 Deficient Mice with a High-Fat/High-Sucrose Diet
Sato, A., Shiraishi, Y., Kimura, T., Osaki, A., Kagami, K., Ido, Y., & Adachi, T. K. (2022) · Antioxidants · doi:10.3390/antiox11071403 · Cited by 8
Exocrine Pancreas Hyperplasia Without Dysplasia in Glucagon Receptor Knockout Mice
Yu, R., Nissen, N. N., & Dhall, D. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182a5dc77 · Cited by 7
Welters, A., & Lammert, E. (2014) · Springer eBooks · doi:10.1007/978-3-7091-0715-7_26 · Cited by 8
Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects
Lebovitz, H. E. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0274 · Cited by 7
Ismail, A., Amer, M. S., & Tawheed, A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i3.107148 · Cited by 7
Hemiplegic Migraines Exacerbated using an Injectable GLP-1 Agonist for Weight Loss
Modestino, E. J., Bowirrat, A., Lewandrowski, K., Sharafshah, A., Badgaiyan, R. D., Thanos, P. K., Baron, D. A., Dennen, C. A., Elman, I., Sunder, K. R., et al. (2024) · Acta Scientific Neurology · doi:10.31080/asne.2024.07.0731 · Cited by 8
GLP-1 Agonist Use in a Patient With an Explainable Cause of Pancreatitis
Brady, S. M., Kane, M. P., & Busch, R. S. (2015) · AACE Clinical Case Reports · doi:10.4158/ep15658.cr · Cited by 7
Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
Kim, M. J., Choi, O. K., Chae, K. S., Lee, H., Chung, S. S., Ham, D., Kim, J., Yoon, K., Park, K. S., & Jung, H. S. (2015) · Islets · doi:10.1080/19382014.2015.1129096 · Cited by 6
Talmon, G. A., Wren, J. D., Nguyen, C. L., & Pour, P. M. (2017) · Pancreas · doi:10.1097/mpa.0000000000000844 · Cited by 6
Chung, M., Chien, H., Peng, S.-J., Chou, Y.-H., Chiang, T., Chang, H.-P., Lee, C., Chen, C., Jeng, Y., Tien, Y., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00111.2022 · Cited by 9
Linagliptin for the treatment of Type 2 diabetes
Tella, S. H., Aktürk, H. K., & Rendell, M. (2013) · Diabetes Management · doi:10.2217/dmt.13.55 · Cited by 6
Metadata
- Authors
- Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C.
- Affiliations
- University of California, Los Angeles (US)
- Departments of Pathology and Pediatrics, College of Medicine, University of Florida, Gainesville, Florida.
- University of Florida Health (US)
- Corresponding author
- Butler, Alexandra E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-06-14
- Volume
- 62
- Issue
- 7
- Pages
- 2595-2604
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3712065
- OpenAlex
- W2137982063
- Cited by
- 457
- References
- 35
- Citations by year
- 2026: 18 · 2025: 20 · 2024: 15 · 2023: 12 · 2022: 19 · 2021: 16 · 2020: 20 · 2019: 21 · 2018: 19 · 2017: 25 · 2016: 34 · 2015: 59 · 2014: 99 · 2013: 80
- FWCI
- 90.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- Larry L. Hillblom Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-061539, R01DK061539, DK059579, #DK077967, R01DK077967, R01DK059579)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- incretin-based therapy, beta-cell mass, pancreatic intraepithelial neoplasia, alpha cell hyperplasia, type 2 diabetes, pancreatic regeneration
- MeSH terms
- Sitagliptin Phosphate, Adenoma, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hyperplasia, Male, Middle Aged, Organ Size, Pancreas, Pyrazines, Triazoles, Neuroendocrine Tumors, Cell Proliferation, Insulin-Secreting Cells, Incretins, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.